The next generation of therapies

PhoreMost’s SITESEEKER® platform enables the inception of first-in-class drug discovery programmes. PhoreMost is developing an internal asset pipeline across core therapeutic focus areas in addition to progressing additional Pharma and Biotech SITESEEKER based collaborations.

Oncology

Glioma, KRAS Synthetic Lethality

Glioma
PM-001, allosteric PLK1 inhibitor in development for Glioma

Ras Synthetic Lethality
PM-002-3, novel SITESEEKER® derived K-RAS synthetic lethal targets

Sentinel Oncology
Therapeutic Area ID Target Validation Chemistry Hit ID Hit 2 Lead Lead Op Preclinical Partnership

Oncology

Glioma, KRAS Synthetic Lethality

Glioma
PM-001, allosteric PLK1 inhibitor in development for Glioma

Ras Synthetic Lethality
PM-002-3, novel SITESEEKER® derived K-RAS synthetic lethal targets

PM-001
Sentinel Oncology
PM-002
PM-003

Immuno oncology

Neoantigen creation

Novel ‘neoantigen inducing’ DNA repair targets

Therapeutic Area ID Target Validation Chemistry Hit ID Hit 2 Lead Lead Op Preclinical Partnership

Immuno oncology

Neoantigen creation

Novel ‘neoantigen inducing’ DNA repair targets

PM-004
PM-005

Targeted Protein Degradation

Multiple functional E3 Ligase ‘linker’ programs

Therapeutic Area ID Target Validation Chemistry Hit ID Hit 2 Lead Lead Op Preclinical Partnership

Targeted Protein Degradation

Multiple functional E3 Ligase ‘linker’ programs

PM-006

Ageing

Autophagy & Senescence

Novel Autophagy and Senescence modulating targets

Therapeutic Area ID Target Validation Chemistry Hit ID Hit 2 Lead Lead Op Preclinical Partnership

Ageing

Autophagy & Senescence

Novel Autophagy and Senescence modulating targets

PM-007
PM-008
PM-009

External

SITESEEKER® collaborations

VernalisNovartisPlexxikonC4X DiscoveryBoehringer IngelheimOtsuka
Therapeutic Area ID Target Validation Chemistry Hit ID Hit 2 Lead Lead Op Preclinical Partnership

External

SITESEEKER® collaborations

PM-010
Vernalis
PM-011
Novartis
PM-012
Plexxikon
PM-013
C4X Discovery
PM-014
Boehringer Ingelheim
PM-015
Otsuka

Oncology & Immuno-Oncology

PhoreMost’s internal oncology assets focus on key oncogenic drivers with multiple previously undruggable targets currently being progressed including multiple K-RAS synthetic lethal targets.

In partnership with Sentinel Oncology, PhoreMost is also progressing allosteric PLK1 inhibitors, currently in development for the treatment of Glioma.

Predominantly focussed on the generation of neoantigens, PhoreMost’s Immuno-oncology programmes are pursuing multiple routes to enhance the body’s response to cancer by making tumours more visible to the immune system.

Targeted Protein Degradation

In applying the SITESEEKER® platform to Targeted Protein Degradation, we have identified a portfolio of novel, functional E3 Ligase binders. Based on these observations, PhoreMost are aiming to develop a suite of small molecule assets that will unlock new E3 ligase based therapeutic strategies.

Ageing

Ageing related diseases are a core future focus of PhoreMost. The SITESEEKER platform is currently active in screening for senescence, autophagy, plaque formation and targeted protein degradation.

External

PhoreMost collaborates at multiple levels. We have SITESEEKER collaborations with Pharma and Biotech in addition to drug discovery and development programmes.

Discover more